Agenus: Botensilimab in advanced melanoma refractory to checkpoint inhibitor therapy

A multicohort, open label, phase 2 study of Botensilimab (AGEN1181) for treatment of advanced melanoma refractory to prior checkpoint inhibitor therapy.

Target group

Adults with advanced skin cancer who have already received an immune-based therapy against skin cancer that has not worked.

Aim of the study

The aim of this study is to investigate the safety and efficacy of botensilimab in patients with skin cancer.